Publikasi Scopus FKUI 2021 per tanggal 31 Maret 2021 (187 artikel)

Curcumin has several pharmacological effects including anti-inflammatory, reduce kidney damage, hepatoprotector, and inhibiting tumor growth in ovarian cancer. The use of curcumin is limited because it has low bioavailability and low capacity to reach target organs. This limitation is overcome by making it in the form of nanoparticles. This study aim to determine curcumin levels on some organ in healthy rat groups and on ovaries at ovarian cancer models rat that given curcumin and curcumin nanoparticles. Measurement of curcumin levels using UPLC-MS/MS. Determination of curcumin level in the organ was carried out in 2 treatment groups, group that received curcumin and group that received curcumin nanoparticles orally with a single dose of 100 mg/kg Body Weight (BW). At 180 minutes, rats were decapitated for liver, kidney and ovaries. The ovarian cancer rats were also divided into 2 groups and given curcumin and curcumin nanoparticles with repeated doses of 100 mg/kgBW/day and after 30 days, ovarian cancer rats were decapitated for the ovaries. In the group that received curcumin, the concentration of curcumin in the liver, kidney and ovaries were less than the detection limit, whereas in the group that received curcumin nanoparticles, the levels of curcumin are 1,866.6±22.60 ng/g in liver, 114.87±13.36 ng/g in kidney and 136.864±11.15 ng/g in ovaries. In ovarian cancer rats, levels of curcumin in the group receiving curcumin is 2.29±1.15 ng/g and 17.76±4.85 ng/g in the group receiving curcumin nanoparticles. Curcumin nanoparticles can increase the distribution of curcumin in liver, kidney, ovaries in healthy rats and in ovaries at ovarian cancer model rats. © 2020. All Rights Reserved.